Advanced search
Publication Cover
Journal of Obstetrics and Gynaecology Volume 43, 2023 - Issue 1
Submit an article Journal homepage
2,136
Views
1
CrossRef citations to date
0
Altmetric
Case Report

Increase in serum creatinine levels after PARP inhibitor treatment

Di Youa Department of Obstetrics and Gynecology, West China Second University Hospital, Sichuan University, Chengdu, China;b Ministry of Education, Key Laboratory of Birth Defects and Related Diseases of Women and Children (Sichuan University), Chengdu, ChinaView further author information
,
Lan Zhonga Department of Obstetrics and Gynecology, West China Second University Hospital, Sichuan University, Chengdu, China;b Ministry of Education, Key Laboratory of Birth Defects and Related Diseases of Women and Children (Sichuan University), Chengdu, ChinaView further author information
,
Rutie Yina Department of Obstetrics and Gynecology, West China Second University Hospital, Sichuan University, Chengdu, China;b Ministry of Education, Key Laboratory of Birth Defects and Related Diseases of Women and Children (Sichuan University), Chengdu, ChinaView further author information
&
Liang Songa Department of Obstetrics and Gynecology, West China Second University Hospital, Sichuan University, Chengdu, China;b Ministry of Education, Key Laboratory of Birth Defects and Related Diseases of Women and Children (Sichuan University), Chengdu, ChinaCorrespondence[email protected]
View further author information
Article: 2171781 | Received 11 Sep 2022, Accepted 19 Jan 2023, Published online: 28 Jan 2023

References

  • Bruin, M.A.C., et al., 2021. A real or apparent decrease in glomerular filtration rate in patients using olaparib? European journal of Clinical Pharmacology, 77 (2), 179–188.
  • Caldecott, K.W., et al., 1996. XRCC1 polypeptide interacts with DNA polymerase beta and possibly poly (ADP-ribose) polymerase, and DNA ligase III is a novel molecular ‘nick-sensor’ in vitro. Nucleic acids Research, 24 (22), 4387–4394.
  • Coleman, R.L., et al., 2017. Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial. The lancet, 390 (10106), 1949–1961.
  • Drew, Y., et al., 2020. Real‐world delivery of Rucaparib to patients with ovarian cancer: recommendations based on an integrated safety analysis of ARIEL2 and Study 10. The oncologist, 25 (1), e109–e119.
  • Fagotti, A., et al., 2020. Randomized trial of primary debulking surgery versus neoadjuvant chemotherapy for advanced epithelial ovarian cancer (SCORPION-NCT01461850). International journal of Gynecological Cancer : official Journal of the International Gynecological Cancer Society, 30 (11), 1657–1664.
  • Jacobson, E.L., et al., 1985. Cellular recovery of dividing and confluent C3H10T1/2 cells from N-methyl-N′-nitro-N-nitrosoguanidine in the presence of ADP ribosylation inhibitors. Carcinogenesis, 6 (5), 715–718.
  • Kikuchi, R., et al., 2013. Prediction of clinical drug–drug interactions of veliparib (ABT-888) with human renal transporters (OAT1, OAT3, OCT2, MATE1, and MATE2K). Journal of Pharmaceutical Sciences, 102 (12), 4426–4432.
  • Konecny, G.E. and Kristeleit, R.S., 2016. PARP inhibitors for BRCA1/2-mutated and sporadic ovarian cancer: current practice and future directions. British journal of Cancer, 115 (10), 1157–1173.
  • LaFargue, C.J., et al., 2019. Exploring and comparing adverse events between PARP inhibitors. The Lancet. Oncology, 20 (1), e15–e28.
  • Laganà, A.S., et al., 2015. Cytogenetic analysis of epithelial ovarian cancer’s stem cells: an overview on new diagnostic and therapeutic perspectives. European journal of Gynaecological Oncology, 36 (5), 495–505.
  • McCormick, A. and Swaisland, H., 2017. In vitro assessment of the roles of drug transporters in the disposition and drug–drug interaction potential of olaparib. Xenobiotica; the Fate of Foreign Compounds in Biological Systems, 47 (10), 903–915.
  • Ray-Coquard, I., PAOLA-1 Investigators., et al., 2019. Olaparib plus bevacizumab as first-line maintenance in ovarian cancer. The New England Journal of Medicine, 381 (25), 2416–2428.
  • Zibetti Dal Molin, G., et al., 2020. Discrepancy in calculated and measured glomerular filtration rates in patients treated with PARP inhibitors. International journal of Gynecological Cancer, 30 (1), 89–93.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.